scPharmaceuticals (NASDAQ:SCPH) Posts Earnings Results, Beats Estimates By $0.09 EPS

scPharmaceuticals (NASDAQ:SCPHGet Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.09, Zacks reports. scPharmaceuticals had a negative net margin of 403.22% and a negative return on equity of 97.18%. The business had revenue of $6.10 million for the quarter, compared to analysts’ expectations of $6.50 million. During the same quarter in the previous year, the business posted ($0.30) earnings per share.

scPharmaceuticals Stock Up 3.6 %

scPharmaceuticals stock traded up $0.16 during trading hours on Wednesday, hitting $4.66. The stock had a trading volume of 553,038 shares, compared to its average volume of 218,675. The stock has a market capitalization of $167.99 million, a P/E ratio of -2.90 and a beta of 0.09. scPharmaceuticals has a 12-month low of $4.01 and a 12-month high of $11.75. The company has a quick ratio of 6.40, a current ratio of 7.08 and a debt-to-equity ratio of 1.04. The stock’s 50-day moving average price is $4.93 and its 200-day moving average price is $5.40.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of scPharmaceuticals in a report on Wednesday.

Get Our Latest Analysis on scPharmaceuticals

About scPharmaceuticals

(Get Free Report)

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.

Further Reading

Earnings History for scPharmaceuticals (NASDAQ:SCPH)

Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with's FREE daily email newsletter.